medicina53巻13号

2016年12月発行

SCOPE

免疫チェックポイント阻害薬のインパクト

著者： 大木遼佑¹ 三浦裕司¹ 高野利実¹

所属機関： ¹虎の門病院臨床腫瘍科

ページ範囲：P.2271 - P.2279

本稿のポイント
・これまで研究されてきた「がん免疫療法」のなかで初めて，免疫チェックポイント阻害薬が明確にがん患者の生存期間を延長することが報告され，世界にインパクトを与えた．
・欧米諸国，本邦でも同剤の研究が進められており，適応が広がってきている．
・効果予測因子は現時点でわかっておらず，適正使用のためにはバイオマーカーの確立が急務である．
・自己免疫疾患に類似した特徴的な有害事象があり，マネジメントには注意を要する．
・きわめて期待される薬剤ではあるが，薬価が高額であり，経済的な問題を含め今後の研究課題はまだ多い．

参考文献

1）国立がん研究センターがん対策情報センター：2015年のがん罹患数，死亡数予測　http://www.ncc.go.jp/jp/information/press_release_20150428.html（2016年9月閲覧）

2）Mellman I, et al：Cancer immunotherapy comes of age. Nature 480：480-489, 2011

3）William MA, Bevan JB：Effector and memory CTL differentiation. Annu Rev Immunol 25：171-192, 2007

4）Pardoll DM：The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12：252-264, 2012

5）Sharma P, Allison JP：Immune checkpoint targeting in cancer therapy；Toward combination strategies with curative potential. Cell 161：205-214, 2015

6）Wing K, et al：CTLA-4 control over Foxp3＋ regulatory T cell function. Science 322：271-275, 2008

7）Okazaki T, et al：A rheostat for immune responses；The unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14：1212-1218, 2013

8）Ribas A：Tumor immunotherapy directed at PD-1. N Engl J Med 366：2517-2519, 2012

9）Brunet JF, et al：A new member of the immunoglobulin superfamily-CTLA-4. Nature 328：267-270, 1987

10）Hodi FS, et al：Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100：4712-4717, 2003

11）Phan GQ, et al：Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100：8372-8377, 2003

12）Hodi FS, et al：Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363：711-723, 2010

13）Robert C, et al：Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364：2517-2526, 2011

14）Ishida Y, et al：Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11：3887-3895, 1992

15）Brahmer JR, et al：Phase I study of single-agent anti-programmed death-1（MDX-1106）in refractory solid tumors；Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28：3167-3175, 2010

16）Topalian SL, et al：Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366：2443-2454, 2012

17）Robert C, et al：Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372：320-330, 2015

18）Weber JS, et al：Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment（CheckMate 037）；A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16：375-384, 2015

19）Hamid O, et al：Safety and tumor responses with lambrolizumab（anti-PD-1）in melanoma. N Engl J Med 369：134-144, 2013

20）Rosenberg JE, et al：Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy；A single-arm, multicentre, phase 2 trial. Lancet 387：1909-1920, 2016

21）Larkin J, et al：Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373：23-34, 2015

22）Ribas A, et al：Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368：1365-1366, 2013

23）Wolchok JD, et al：Guidelines for the evaluation of immune therapy activity in solid tumors；Immune-related response criteria. Clin Cancer Res 15：7412-7420, 2009

24）Schadendorf D, et al：Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33：1889-1894, 2015

25）Ribas A, et al：Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315：1600-1609, 2016

26）Zaretsky JM, et al：Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375：819-829, 2016

27）Weber JS, et al：Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30：2691-2697, 2012

28）Brahmer JR, et al：Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366：2455-2465, 2012

29）Nishino M, et al：Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 373：288-290, 2015

30）Michot JM, et al：Immune-related adverse events with immune checkpoint blockade；A comprehensive review. Eur J Cancer 54：139-148, 2016

31）Morrison C：‘Financial toxicity' looms as cancer combinations proliferate. Nat Biotechnol 33：783-784, 2015

32）Couzin-Frankel J：Cancer immunotherapy. Science 342：1432-1433, 2013